DiscoverThe Evidence Based Rheumatology Podcast
The Evidence Based Rheumatology Podcast
Claim Ownership

The Evidence Based Rheumatology Podcast

Author: Michael Putman

Subscribed: 320Played: 8,502
Share

Description

A podcast for physicians about evidence based medicine in rheumatology. Each week we'll critique and apply a paper in the medical literature.
133 Episodes
Reverse
Fun study this week on a disease I haven't discussed in quite some time. Leflunomide plus hydroxychloroquine beat placebo on ESSDAI in RepurpSS-II, a small Lancet Rheumatology trial in systemically active Sjögren’s disease. But pain, fatigue, and dryness didn’t budge. I break down ESSDAI vs ESSPRI vs STAR vs CRESS, the salivary flow cutoff to memorize, and who I’d actually treat with this combination. RepurpSS-II, Lancet Rheumatology 2026 RepurpSS-I, Lancet Rheumatology 2020
A new therapy for SLE! This one is a CD40-CD40L blocker, which has some nice new-things to inhibit. The study itself was a qualified success and the podcast got a bit more rant-y than it should have been, but hopefully you get a kick out of it.  Paper: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00691-4/fulltext  
Another day, another B cell drug. This one adds an interesting option for IgG4-RD, offering a "maybe less efficacious maybe less toxic" pathway. I could see folks being excited for this, especially in a disease where non-scary-manifestations are relatively common.  Also, check out boardsbank.com!  Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2601337
Big trial this week in the NEJM investigating the IL17 inhibitor secukinumab in PMR. Well worth a read, I would bet on FDA approval in the near future. Some interesting tidbits and of course a weird safety thing we now have to grapple with.  Be sure to go to boardsbank.com! Free rheumatology board review, >1000 questions!  Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2602567
E135: IL17 and a GLP1?

E135: IL17 and a GLP1?

2026-04-3011:03

Really interesting study this week comparing the IL17 inhibitor ixekizumab WITH the GLP1 inhibitor tirzepatide to ixekizumab alone. Raises some interesting questions about what worked here and whether or not it matters how it worked.    Paper: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.70134 Newsletter: http://autoimmunedevreport.com/  
loading
Comments